Development of a Novel Anti-HIV Oligonucleotide

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$98,800.00
Award Year:
1995
Program:
SBIR
Phase:
Phase I
Contract:
1 R43 AI38788-01,
Agency Tracking Number:
29153
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Triplex Pharmaceutical
9391 Grogans Mill Road, The Woodlands, TX, 77380
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
Thomas Wallace
() -
Business Contact:
() -
Research Institution:
n/a
Abstract
AIDS is a fatal disorder of the immune system caused by the HIV and is a widespread epidemic. The lobjective of this work is to treat human AIDS patients with a novel oligonucleotide (T30177) that haanti-HIV activity. We will perform preclinical animal pharmacology studies, including pharmacokinetiand toxicity studies in mice. One of these aims includes investigating a novel in vivo route of admioligonucleotides. Although there are a number of drugs that are currently available for the treatmenhave limited effectiveness and only delay the progression to death of AIDS patients. There is a greadevelopment of more effective and novel drugs for the treatment of AIDS. T30177 may provide significpresently available HIV drugs because it has a novel mechanism of action, it is active against AZT-rbeen shown in pilot animal studies to have a long half-life, good stability, and low toxicity.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government